Optimization of a Ganglion Cell-Based Optogenetic Therapy for Vision Restoration – Study by the EKFZ

Degenerative retinal diseases such as Retinitis pigmentosa (RP) and geographic atrophy (GA) affect approximately 10 million people worldwide and lead to significant and often irreversible vision loss.
Note: The prospective observational study began in March 2025 and is designed for five years (Clinical-Trials.gov ID: NCT07056738). Interested study participants can still register.